Biotest Aktiengesellschaft (HAM:BIO3)

Market Cap	1.40B
Revenue (ttm)	635.20M
Net Income (ttm)	-24.50M
Shares Out	n/a
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	23.49
Dividend	0.04 (0.13%)
Ex-Dividend Date	Jul 3, 2025

Volume	131
Average Volume	820
Open	30.20
Previous Close	30.20
Day's Range	30.20 - 30.60
52-Week Range	27.10 - 31.00
Beta	n/a
RSI	51.03
Earnings Date	Aug 4, 2025

About HAM:BIO3

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company’s products also comprise Cytotect CP biotest for cytomegalovirus infection; Fovepta for immun...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1946
• Employees: 2,495
• Stock Exchange: Hamburg Stock Exchange
• Ticker Symbol: BIO3

Financial Performance

In 2024, HAM:BIO3's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.